These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15356061)

  • 1. Beta-cell insulin secretory response to oral hypoglycemic agents is blunted in humans in vivo during moderate hypoglycemia.
    Aldhahi W; Armstrong J; Bouche C; Carr RD; Moses A; Goldfine AB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4553-7. PubMed ID: 15356061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
    Hu S; Wang S; Fanelli B; Bell PA; Dunning BE; Geisse S; Schmitz R; Boettcher BR
    J Pharmacol Exp Ther; 2000 May; 293(2):444-52. PubMed ID: 10773014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes.
    Fuhlendorff J; Rorsman P; Kofod H; Brand CL; Rolin B; MacKay P; Shymko R; Carr RD
    Diabetes; 1998 Mar; 47(3):345-51. PubMed ID: 9519738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of repaglinide upon nutrient metabolism, biosynthetic activity, cationic fluxes and insulin release in rat pancreatic islets.
    Louchami K; Jijakli H; Sener A; Malaisse WJ
    Res Commun Mol Pathol Pharmacol; 1998 Feb; 99(2):155-68. PubMed ID: 9583090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal.
    Cozma LS; Luzio SD; Dunseath GJ; Langendorg KW; Pieber T; Owens DR
    Diabetes Care; 2002 Aug; 25(8):1271-6. PubMed ID: 12145220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.
    Degn KB; Brock B; Juhl CB; Djurhuus CB; Grubert J; Kim D; Han J; Taylor K; Fineman M; Schmitz O
    Diabetes; 2004 Sep; 53(9):2397-403. PubMed ID: 15331551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
    Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
    Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide.
    Hu S; Wang S; Dunning BE
    Int J Exp Diabetes Res; 2001; 2(1):63-72. PubMed ID: 12369728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
    Nauck MA; Heimesaat MM; Behle K; Holst JJ; Nauck MS; Ritzel R; Hüfner M; Schmiegel WH
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1239-46. PubMed ID: 11889194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective loss of glucose-induced amplification of insulin secretion in mouse pancreatic islets pretreated with sulfonylurea in the absence of fuels.
    Urban KA; Panten U
    Diabetologia; 2005 Dec; 48(12):2563-6. PubMed ID: 16283243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequency.
    Juhl CB; Pørksen N; Hollingdal M; Sturis J; Pincus S; Veldhuis JD; Dejgaard A; Schmitz O
    Diabetes Care; 2000 May; 23(5):675-81. PubMed ID: 10834429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of action of a new class of insulin secretagogues.
    Malaisse WJ
    Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S140-3. PubMed ID: 10522840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic islet responsiveness to D-glucose after repeated administration of repaglinide.
    Laghmich A; Ladrière L; Malaisse-Lagae F; Malaisse WJ
    Eur J Pharmacol; 1998 May; 348(2-3):265-70. PubMed ID: 9652342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.
    Hollingdal M; Sturis J; Gall MA; Damsbo P; Pincus S; Veldhuis JD; Pørksen N; Schmitz O; Juhl CB
    Diabet Med; 2005 Oct; 22(10):1408-13. PubMed ID: 16176204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency.
    Østergård T; Degn KB; Gall MA; Carr RD; Veldhuis JD; Thomsen MK; Rizza RA; Schmitz O
    J Clin Endocrinol Metab; 2004 Jan; 89(1):297-302. PubMed ID: 14715864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of glucagon secretion at low glucose concentrations: evidence for adenosine triphosphate-sensitive potassium channel involvement.
    Muñoz A; Hu M; Hussain K; Bryan J; Aguilar-Bryan L; Rajan AS
    Endocrinology; 2005 Dec; 146(12):5514-21. PubMed ID: 16123162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Repaglinide (NN-623)].
    Matsuda M; Kaku K
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():555-8. PubMed ID: 12387050
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of repaglinide on insulin secretion in islets from rats infused for two days with a hypertonic solution of D-glucose.
    Louchami K; Ladrière L; Jijakli H; Malaisse WJ
    Endocrine; 1998 Jun; 8(3):247-50. PubMed ID: 9741829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2].
    Rutten GE
    Ned Tijdschr Geneeskd; 2001 Aug; 145(32):1547-50. PubMed ID: 11525087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.